Question 16344 — pharmacy and medications

Summary

Mr. Ian Boucard draws the attention of the Minister of Solidarity and Health to the shortages of medicines faced by a certain number of sick people in France. Indeed, a clear increase of more than 30% in stock shortages of medicines was noted in France for the year 2017 compared to the year 2016. This is mainly explained by the desire of pharmaceutical companies to to relocate their production to Asia but also by their disinterest in treatments for which they will no longer have exclusivity. However, these stock shortages concern drugs of major therapeutic interest such as anticancer drugs, antibiotics, antiparkinsonian drugs and vaccines. These shortages endanger the proper functioning of the health system and therefore lead to a loss of chance of recovery. unacceptable for patients whose treatments are out of stock. In fact, the shortage of certain medications can have extremely serious consequences for sick people. This is the case, for example, for those who used the anticancer drug ametycin and who must undergo a cystectomy because they find themselves without their medication. Furthermore, these shortages can in some cases last a very long time, such as this is currently the case for sinemet, a drug used to treat Parkinson's disease, which will not be restocked before March 2019. This is why, he asks what measures the Government intends to take with pharmaceutical laboratories so that France preserves its health independence and allows its citizens to have access to their treatments beyond financial issues which cannot be an obstacle to care.

Machine translation from French. The official text remains authoritative.

Timeline

No timeline events have been ingested for this record yet.

Votes

No vote records are attached yet.

Versions

No version snapshots stored. Document URLs remain at the source.

Documents

No documents linked.

Sponsors

No sponsors or actors listed by the source.

Related records

No cross-record relationships stored yet.